Option A
Watchful Waiting
Appropriate for some patients, but it leaves others living with uncertainty while disease remains untreated.
InfrajectX is building a first-in-class procedural platform — combining picosecond infrared laser access, real-time ultrasound guidance, and localized therapy delivery — to open a new focal treatment pathway designed to preserve surrounding anatomy while enabling immunotherapy and localized drug treatment, rather than relying on tissue destruction alone.
Too serious to just watch. Too early to remove.
Patients need an option between surveillance and radical treatment. Focal therapies aim to fill that gap, but current platforms still focus mainly on destroying tissue in place instead of reducing recurrence risk through localized drug delivery and immunotherapy.
Appropriate for some patients, but it leaves others living with uncertainty while disease remains untreated.
Focal treatment is the right place to intervene, but current platforms still come with real limitations.
Effective, but often disproportionate for localized disease and associated with meaningful quality-of-life tradeoffs.
PIRL-PRO is designed to improve on focal therapy by combining precise access with localized drug delivery and immunotherapy, aiming not just to damage the tumor but to treat the remaining cancer risk more intelligently.
It is also intended for the same clinic-based workflow where urologists already perform ultrasound and MRI-fusion biopsies, rather than forcing treatment into a large hospital MRI setting.
PIRL-PRO is designed to answer the core shortcomings of current focal therapy platforms: greater procedural precision, a more practical image-guided workflow, and the ability to deliver localized therapy within the same intervention.
Picosecond infrared laser interaction creates controlled tissue access through vibrational excitation rather than thermal injury, with the goal of minimizing collateral necrosis and preserving surrounding functional anatomy for accurate, repeatable treatment.
Real-time ultrasound guidance is intended to support lesion targeting and therapy delivery in the same urology clinics where ultrasound and MRI-fusion biopsies are already performed, without requiring MRI-dependent workflow in a large hospital setting.
By enabling direct delivery of immunotherapy and other therapeutic agents at the lesion, PIRL-PRO is designed to move focal therapy beyond ablation alone and toward localized biologic and drug-based treatment with lower systemic exposure. The platform architecture is extensible to other solid-tumor indications beyond prostate cancer.
Organ-sparing focal intervention between surveillance and radical treatment — with the aim of treating disease locally while preserving quality of life.
An image-guided procedural platform designed for the same clinics where urologists already perform ultrasound and MRI-fusion biopsies.
Extensible architecture for localized immunotherapy and drug delivery beyond prostate cancer — a foundation for a multi-indication oncology procedural platform.
“The goal is not a better way to destroy tissue in place — it’s a smarter procedure. One that reaches the lesion precisely, enables immunotherapy and localized drug treatment, preserves what doesn’t need treatment, and aims to eliminate the remaining risks of focal cancer therapy.”InfrajectX — Platform Thesis
InfrajectX is being developed around a focused thesis: localized prostate cancer needs a better option between passive surveillance and radical treatment, one designed to enable immunotherapy and localized drug delivery rather than stopping at tissue ablation. The effort is shaped by experience across medtech invention, procedural thinking, translational science, and commercialization.
The team brings together expertise across laser science, procedural medicine, imaging-guided intervention, product development, and company building — with the goal of translating a technically differentiated platform into a clinically deployable oncology procedure.
InfrajectX is engaging with aligned investors and strategic partners. We welcome conversations with those who share our vision for transforming focal oncology care.